SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT00899743

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Determining the Clinicopathological Significance of CaMKIIgamma Activation in AML

RATIONALE: Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is looking at blood and bone marrow samples from patients with previously untreated primary acute myeloid leukemia.

NCT00899743 Leukemia
MeSH:Leukemia
HPO:Leukemia

4 Interventions

Name: polyacrylamide gel electrophoresis

Description: polyacrylamide gel electrophoresis
Type: Genetic

Name: western blotting

Description: western blotting
Type: Genetic

Name: immunologic technique

Description: immunologic technique
Type: Other

Name: laboratory biomarker analysis

Description: laboratory biomarker analysis
Type: Other


Primary Outcomes

Measure: Association of specific clinicopathological variables and outcomes with calmodulin-dependent protein kinase II-╬│ (CaMKII╬│) activation (autophosphorylation)

Time: upon receipt of specimens

Time Perspective: Retrospective


There is one SNP

SNPs


1 S9333A

S9333A Study of Blood and Bone Marrow Samples From Patients With Previously Untreated Primary Acute Myeloid Leukemia RATIONALE: Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. --- S9333A ---



HPO Nodes


HPO: